All Photos(1)

Documents

Y0000626

Ketorolac trometamol for peak identification

Name: Ketorolac trometamol for peak identification
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Ketorolac tris salt, (±)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid tris salt, Toradol

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₁₅H₁₃NO₃ · C₄H₁₁NO₃

CAS Number:

74103-07-4

Molecular Weight:

376.40

MDL number:

MFCD00887595

UNSPSC Code:

41116107

PubChem Substance ID:

329831061

NACRES:

NA.24

grade

pharmaceutical primary standard

API family

ketorolac

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

NC(CO)(CO)CO.OC(=O)C1CCn2c1ccc2C(=O)c3ccccc3

InChI

1S/C15H13NO3.C4H11NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13;5-4(1-6,2-7)3-8/h1-7,11H,8-9H2,(H,18,19);6-8H,1-3,5H2

InChI key

BWHLPLXXIDYSNW-UHFFFAOYSA-N

Gene Information

human ... PTGS1(5742) , PTGS2(5743)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analytical Reference Standards

Pharmacopeia & Metrological Institute Standards

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Ketorolac trometamol for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.

Description

Pricing

1356326

1356315

1356337

1356348

PHR2493

PHR2494

Pictograms

GHS06

Signal Word

Danger

Hazard Statements

H301,H315,H319,H335

Precautionary Statements

P261 - P264 - P270 - P301 + P310 - P302 + P352 - P305 + P351 + P338

Hazard Classifications

Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

WGK

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A double-blind randomized controlled trial of continuous intravenous Ketorolac vs placebo for adjuvant pain control after renal surgery.

Gwen M Grimsby et al.

Mayo Clinic proceedings, 87(11), 1089-1097 (2012-10-13)

To evaluate the efficacy and safety of a novel, continuous intravenous infusion of ketorolac, a powerful nonopioid analgesic, for postoperative pain control. A prospective, double-blind, randomized, placebo-controlled trial of a continuous infusion of ketorolac tromethamine in 1 L of normal

Ketorolac tromethamine formulations: an overview.

V R Sinha et al.

Expert opinion on drug delivery, 6(9), 961-975 (2009-08-12)

Ketorolac tromethamine (KT) is a non-steroidal anti-inflammatory drug that belongs to the class of heteroaryl acetic acid derivatives. It is a non-selective cyclooxygenase (COX) inhibitor, being marketed in the racemate form. Most of its analgesic and COX inhibitory activity is

Intracranial hemorrhage requiring surgery in neurosurgical patients given ketorolac: a case-control study within a cohort (2001-2010).

Giuseppina Magni et al.

Anesthesia and analgesia, 116(2), 443-447 (2013-01-11)

Ketorolac tromethamine (ketorolac) is a nonsedating drug with potent analgesic and moderate anti-inflammatory activity, which does not increase the sedation level. The safety of ketorolac with respect to risk of bleeding has been demonstrated in large numbers of patients undergoing

Efficacy and safety of indomethacin 0.1% eye drops compared with ketorolac 0.5% eye drops in the management of ocular inflammation after cataract surgery.

Michel Weber et al.

Acta ophthalmologica, 91(1), e15-e21 (2012-09-14)

To determine whether indomethacin 0.1% eye drops are at least as effective as ketorolac 0.5% eye drops in treating ocular inflammation following cataract surgery. Prospective, multicenter, investigator-masked, parallel-group, randomized, active-controlled clinical trial. Cataract patients were randomized in a 1:1 ratio

The impact of pregnancy on urinary ketorolac metabolites after single intravenous bolus.

Aida Kulo et al.

European journal of drug metabolism and pharmacokinetics, 38(1), 1-4 (2012-11-28)

Compared to female volunteers or postpartum, ketorolac clearance is higher at delivery. To explore the alterations that explain this higher clearance, urinary ketorolac metabolites collected at delivery (n = 40) were compared to female volunteers (unpaired, n = 8) or postpartum (paired, n = 8) following

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service